The company will present data from the Phase I trial of teclistamab in an oral session at the ASCO virtual meeting later this month. The drug, a bispecific monoclonal antibody against the antigen BCMA, is a potential competitor to a similar therapy developed by Amgen.
Janssen's iSTEP platform is part of an ongoing effort by pharma companies to reduce the cost of drug development and address the complexities of having multiple sites for these trials in different countries.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.